Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma. The LOGIC Study

NCT03528876 is registered in ClinicalTrials.gov with University of Saskatchewan as lead sponsor.

NCT NCT03528876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03528876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma. The LOGIC Study
Lead sponsor
University of Saskatchewan
Phase
Phase 2
Overall status
Terminated
Start date
September 1, 2018
Completion date
October 29, 2020
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gastro-esophageal adenocarcinoma